DPZ Signs License Agreement with Biogen Idec

Munich/Göttingen, (PresseBox) - The German Primate Center (DPZ) and its technology transfer partner Ascenion announced today the signing of a license agreement providing Biogen Idec with exclusive, worldwide rights to a patent portfolio directed to a recombinant virus-like particle (VLP) containing VP1 protein for the detection of antibodies to JC virus (JCV). The license provides authorization for Biogen Idec's use of this VLP in a test in the context of multiple sclerosis (MS) and, optionally, certain other indications. In return, the DPZ receives undisclosed upfront and milestone payments as well as royalties related to the VLP's use.

DPZ's patents relating to JCV cover certain diagnostic and therapeutic applications of recombinant VP1.These proteins self-assemble into VLPs with the typical JCV morphology and can be used as highly specific antigens for detecting anti-JCV antibodies in human serum or blood.

"The DPZ has single-mindedly built and sustained its IP portfolio on JCV over many years," said Michael Lankeit, Administrative Director of the DPZ. "We are delighted to partner with Biogen Idec on this important initiative."

Press releases you might also be interested in

Subscribe for news

The subscribtion service of the PresseBox informs you about press information of a certain topic by your choice at a choosen time. Please enter your email address to receive the email with the press releases.

An error occurred!

Thank you! You will receive a confirmation email within a few minutes.

I want to subscribe to the gratis press mail and have read and accepted the conditions.